Ketamine Therapy for Depression: What the Research Actually Says

Ketamine has been one of the most over-hyped and most under-explained treatments in mental health over the last five years. Both things can be true. The marketing is loud, the research is real, and the average patient has almost no way to tell which clinic is running an evidence-based protocol and which one is renting a strip-mall suite.

The core finding from the treatment-resistant depression research is consistent. Across multiple controlled trials, roughly half to two-thirds of people who have failed multiple antidepressants respond meaningfully to a course of ketamine, with response measured as a substantial reduction in depression scores. A meaningful subset achieve remission. That is a remarkable response rate compared to a sixth or seventh SSRI trial, which historically shows response rates in the low double digits.

Spravato is the FDA-approved nasal spray version of esketamine. It is delivered in a clinic, monitored for two hours, and covered by most insurance plans for treatment-resistant depression. Off-label IV and intramuscular ketamine, used at most ketamine clinics, is not FDA-approved for depression, but it has substantially more flexibility in dosing and is often paired with psychotherapy. The clinical responses are broadly comparable, with some research suggesting IV ketamine may have a slightly faster or stronger initial effect.

Duration of response is the honest weak point. Most people do not get one course of ketamine and stay better forever. The typical pattern is an initial loading series of six infusions over two to three weeks, followed by maintenance dosing every few weeks to every few months, depending on the person. Some people taper off entirely. Some people maintain indefinitely. The decision is clinical and personal, not algorithmic.

Side effects in a clinical setting are usually short-lived: dissociation during the infusion, mild nausea, an elevated blood pressure that returns to baseline within an hour. Ketamine has abuse potential, which is part of why it is delivered in a monitored setting and not as a take-home prescription. People with active psychosis, uncontrolled hypertension, or certain cardiac conditions should not pursue it. A good clinic will screen carefully and decline patients who aren't appropriate.

What the research does not show: that ketamine is a one-and-done cure, that every clinic is equivalent, or that the experience itself is therapeutic without an integration framework. The clinics with the best outcomes consistently pair ketamine with structured psychotherapy and clear post-session integration. The clinics with the worst outcomes treat it like a transaction.

If you're considering ketamine, the right question is not just whether it works. The right question is which clinic, which protocol, and what kind of support around it. That is exactly the kind of question a placement navigator can answer faster than you can.